News

For Immediate Release: August 10, 2015

Contact
Mary Kuramoto
513-579-9911 x2523
m.kuramoto@medpace.com

Medpace Continues to Grow in Europe with Expanded Facilities in Stirling, United Kingdom

Cincinnati, OH. (August 10, 2015) – Medpace, Inc. has announced the relocation of its existing office in Stirling, Scotland in the United Kingdom. The new office is roughly three times the size of the former facility, allowing for significant growth in Data Management, Bio Statistics, Quality Assurance, Regulatory Affairs, Clinical Operations, and Safety. Together with the recently expanded London office, Medpace continues to invest in additional capacity for our operations globally. The UK offices in London and Stirling, Scotland, now houses close to 130 Medpace employees.

Medpace has focused expansion efforts in Europe over the past few years. The European activities have included adding additional clinical research professionals and expanding facilities in the United Kingdom, Poland, Russia, France, Germany and future significant office expansions planned for 2015/2016 in Leuven (Belgium), Prague (Czech Republic), Madrid (Spain). Medpace offices in Europe offer clinical operational support for a rapidly expanding Global and European market. Medpace established its first European office in the Czech Republic in 2005. Medpace employees in Europe now account for over one third of Medpace global employees.

With 12 European offices serving 30 EU countries, Medpace continues to grow and supply innovative support for studies in oncology, cardio metabolic, infectious disease, CNS, and other growing therapeutic areas. All European offices are fully integrated with Medpace global development services.

New Location in Stirling

Wallace House

17-21 Maxwell Place

Stirling

Scotland

FK8 1JU

Main office no: +44 (0)1786 460400

Main office fax: +44 (0)208 741 6496

ABOUT MEDPACE

Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information, please visit www.medpace.com